NeuroPace Past Earnings Performance
Past criteria checks 0/6
NeuroPace has been growing earnings at an average annual rate of 5.1%, while the Medical Equipment industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 19.2% per year.
Key information
5.09%
Earnings growth rate
93.67%
EPS growth rate
| Medical Equipment Industry Growth | 8.90% |
| Revenue growth rate | 19.18% |
| Return on equity | -112.79% |
| Net Margin | -21.47% |
| Next Earnings Update | 12 May 2026 |
Recent past performance updates
Recent updates
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have lifted their price target on NeuroPace from $15.63 to $18.00, citing updated expectations for revenue growth and profit margins, as well as a higher future P/E multiple following recent Street research coverage. Analyst Commentary The latest Street research on NeuroPace reflects constructive top line expectations alongside a watchful stance on execution and valuation risk.
NPCE: Refreshed Growth Assumptions And Richer P E Outlook Will Support Upside
Analysts have increased their average price target on NeuroPace by $1, citing updated assumptions that include slightly stronger revenue growth, a revised discount rate, a lower projected profit margin and a higher future P/E multiple. Analyst Commentary Bullish analysts are highlighting NeuroPace as a name where recent research work has led to more constructive views on both execution and valuation.
NPCE: Higher Margin Conviction And Reaffirmed Guidance Will Support More Optimistic Outlook
Analysts have modestly increased their price target on NeuroPace by $1, citing refreshed assumptions around long term profit margins and a slightly higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see room for long term margin improvement, which supports their willingness to apply a slightly higher future P/E multiple in their models.NPCE: Expanded Epilepsy Indication And Guidance Reaffirmation Will Support More Optimistic Outlook
Analysts increased their price target on NeuroPace by about $0.45 to $19.88, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target of about $19.88 as better aligned with their revised expectations for revenue growth and margin progress in the current model.NPCE: Refined Risk And Margin Outlook Will Support Future Upside Potential
Analysts lifted their price target on NeuroPace by $1, citing updated assumptions around the discount rate, profit margin, and future P/E that refine how they view the company’s risk and earnings potential. Analyst Commentary Recent Street research points to a more constructive tone around NeuroPace, with bullish analysts fine tuning their models rather than making wholesale changes.NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have raised their price target for NeuroPace by about $1 to approximately $16, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. Analyst Commentary Even with the roughly $1 move in the price target to about $16, some research commentary still reads as cautious rather than outright bullish.NPCE: Updated Seizure Trial Data Will Support A More Optimistic Outlook
Analysts have nudged their price target on NeuroPace higher to about US$19.43 from roughly US$17.13, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that are consistent with recent Street research. Analyst Commentary Analysts updating their models around NeuroPace are using the revised price target to reflect refreshed assumptions on valuation, growth expectations, and execution risks rather than a wholesale change in thesis.NPCE: Broader Epilepsy Indication And Trial Evidence Will Support Future Upside
Analysts now see NeuroPace as fairly valued around US$22.00 per share. They have made only slight tweaks to assumptions for discount rate, revenue growth, profit margin and future P/E, refining rather than overhauling their previous price target view.NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry?
Jan 09
NPCE: Expanded Epilepsy Indication And Trial Data Will Support Bullish Outlook
Analysts lifted their price target on NeuroPace from US$20.00 to US$22.00, citing changes in their fair value estimate along with updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News NeuroPace filed a Premarket Approval Supplement with the U.S. FDA to expand the labeled indication for its RNS System to antiseizure medication resistant idiopathic generalized epilepsy with generalized tonic clonic seizures, supported by preliminary NAUTILUS trial data showing a 77% median reduction in GTC seizures at 18 months and a favorable safety profile.NPCE: Future Performance Will Reflect Trial Data Strength And Moderate Risk
Analysts have raised their price target on NeuroPace from 13.00 dollars to 15.00 dollars. This reflects modestly lower perceived risk, slightly stronger long term margin potential, and still supportive valuation multiples despite a tempered revenue growth outlook.Revenues Tell The Story For NeuroPace, Inc. (NASDAQ:NPCE) As Its Stock Soars 25%
Nov 19NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 25% Price Jump
Sep 19NeuroPace, Inc. (NASDAQ:NPCE) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 14NeuroPace: Volatile, Uncertain, But Promising
Jun 29Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Jun 19NeuroPace, Inc. (NASDAQ:NPCE) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
May 13
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 07NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump
Jan 24After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar
Dec 04Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results
Nov 14Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Nov 07NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch
Aug 03Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Apr 12NeuroPace: Picking Up The Pace
Feb 25Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge
Jan 22NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company
Apr 17Revenue & Expenses Breakdown
How NeuroPace makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 100 | -21 | 66 | 28 |
| 30 Sep 25 | 95 | -24 | 64 | 27 |
| 30 Jun 25 | 89 | -26 | 61 | 26 |
| 31 Mar 25 | 84 | -25 | 57 | 25 |
| 31 Dec 24 | 80 | -27 | 57 | 24 |
| 30 Sep 24 | 76 | -28 | 57 | 23 |
| 30 Jun 24 | 72 | -30 | 56 | 22 |
| 31 Mar 24 | 69 | -32 | 56 | 21 |
| 31 Dec 23 | 65 | -33 | 55 | 21 |
| 30 Sep 23 | 60 | -38 | 55 | 20 |
| 30 Jun 23 | 55 | -42 | 54 | 21 |
| 31 Mar 23 | 49 | -46 | 52 | 22 |
| 31 Dec 22 | 46 | -47 | 51 | 22 |
| 30 Sep 22 | 44 | -47 | 50 | 22 |
| 30 Jun 22 | 43 | -43 | 46 | 21 |
| 31 Mar 22 | 45 | -39 | 43 | 20 |
| 31 Dec 21 | 45 | -36 | 39 | 18 |
| 30 Sep 21 | 45 | -30 | 34 | 17 |
| 30 Jun 21 | 47 | -26 | 32 | 16 |
| 31 Mar 21 | 42 | -26 | 28 | 15 |
| 31 Dec 20 | 41 | -24 | 28 | 16 |
| 31 Dec 19 | 37 | -30 | 30 | 18 |
Quality Earnings: NPCE is currently unprofitable.
Growing Profit Margin: NPCE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NPCE is unprofitable, but has reduced losses over the past 5 years at a rate of 5.1% per year.
Accelerating Growth: Unable to compare NPCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NPCE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (13.2%).
Return on Equity
High ROE: NPCE has a negative Return on Equity (-112.79%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/05 00:05 |
| End of Day Share Price | 2026/05/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeuroPace, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Polark | Baird |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |